The RiverWalk team brings a synergistic combination of expertise in cancer research and early drug development that will facilitate the development of these molecules. Dr. Jiang and Ms. Webb have a joint history of successful drug development in two programs that both advanced to clinical trials. They have an established productive collaboration and a complementary set of skills and expertise when working together. Additionally, RiverWalk has a highly-experienced team of drug development consultants and advisors with deep expertise in small molecules to assist in the development process.
Johanna Webb, President, is an experienced Drug Development Project Manager with a demonstrated history of working in the biotechnology industry. Johanna is skilled in project management (30+ years), technology evaluation, pre-clinical development, rare pediatric and orphan diseases, and regulatory submission preparation. She holds a Master of Science (MS) in Biotechnology from The University of Texas at San Antonio and Bachelor of Science degrees in Biochemistry and Chemical Engineering from Texas A&M University. Ms. Webb was previously a Engineering Project Manager for McDonnell Douglas on the space station environmental systems, the President of Aspen Consulting Group, and a Commercialization Assessment Consultant for UT Health San Antonio. Immediately before joining the RiverWalk team, she was the Associate Director of Drug Development Project Management for AlaMab Therapeutics, a clinical-stage start-up biotech company. There she was responsible for the completion of pre-IND and IND documents on two different projects, the completion of Orphan Drug and Rare Pediatric Disease Designation filings, all of which were successfully awarded by the FDA, and acted as the leader of multi-disciplined teams of consultants, clinicians, and CROs to develop and implement clinical development plans and the resulting regulatory filings.
Dr. Jean Jiang, Founder & CSO, is the Zachry Distinguished University Professor in Cancer Research at UT Health San Antonio with 25+ years in cancer research. Dr. Jiang previously co-founded AlaMab Therapeutics, where she worked with Ms. Webb. AlaMab advanced 2 assets into clinical trials due in large part to Dr. Jiang’s contributions and Ms. Webb’s leadership. Dr. Jiang received her Ph.D. from the State University of New York at Stony Brook and did her postdoctoral training at Harvard Medical School. She was a research faculty there before she joined UT Health San Antonio as a faculty member. She has authored 170+ peer-reviewed publications with over 20,000 citations. Her research primarily focuses on connexin hemichannels in bone and cancer bone metastasis. Her lab has developed both cell-based and in vivo animal models. Her research has been continuously funded by grants from the NIH, DoD, and other funding agencies. She is a Fellow of the American Association for Advancement of Science (AAAS) and National Academy of Inventors (NAI), and the recipient of the Cancer Therapeutic Research Center Discovery of the Year Award, Master Research Award for Distinguished Researcher, and Presidential Distinguished Senior Research Award. She has served as an associate and an editorial board member for multiple journals including eLife, the Journal of Biological Chemistry, Matrix Biology, and BMC Cell Biology, as well as a member of many US and international research review and advisory panels.